Skip to content
Menu

Brainstorm Cell Therapeutics Inc. BCLI

Full chart Compare
Set alert

Price alert · BCLI

All alert types
0.84 USD -0.06 (-6.67%)

Regular-session close

0.67 -0.17 -20.23%

After hours · Nov 19, 4:00 PM ET

0.84 Day range 0.86
0.46 52-week range 1.69
YTD
+52.73%
1 year
+35.48%

 

No chart data for this range yet.
Market cap
9.27M
EPS (ttm)
-0.93
Shares out
5.70M
Forward P/E
-0.91
YTD return
+52.73%
1-year return
+35.48%
50-day average
1.70
200-day average
4.88
Enterprise value
3.92M
Volume
3.50K
Avg volume
18.53K
Open
0.86
Previous close
0.90
Day's range
0.84 – 0.86
52-week range
0.46 – 1.69
Beta
0.39
Analysts
Buy
Price target
23.45 (+2691.7%)

Key statistics

Free cash flow
-8.45M
Total cash
3.47M
Total debt
962.00K
Short % of float
2.19%

Fundamental scorecard

2 of 25 checks passed on BCLI’s reported financials

ValueGrowthProfitabilityHealthDividend

2of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Mar 31, 2025.

Financials — quick view

All financials
BCLI Revenue — quarterly 0
BCLI Net income — quarterly -2.86M
BCLI EPS — quarterly -0.45

Earnings

BCLI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.45-1.80-1.35-300.00%
Aug 14, 2024Jun 1, 2024-0.60-0.600.000.00%
May 14, 2024Mar 1, 2024-1.05-0.75+0.30+28.57%
Apr 1, 2024Dec 1, 2023-2.25-1.65+0.60+26.67%
Nov 14, 2023Sep 1, 2023-2.10-2.100.000.00%
Aug 14, 2023Jun 1, 2023-2.25-1.95+0.30+13.33%

Upgrades / downgrades

BCLI analyst upgrades and downgrades
DateFirmActionFromTo
Jul 11, 2024Maxim GroupupHoldBuy
Sep 28, 2023Maxim GroupdownBuyHold
Mar 31, 2023Maxim Groupmain—Buy
Feb 5, 2021Maxim GroupupHoldBuy
May 15, 2018HC Wainwright & Co.init—Buy
Aug 17, 2017Maxim Groupmain—Buy

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on BCLI — it syncs with the Stock Master app.

Insider holders

BCLI insider holders
InsiderRelationLatest transactionDateShares held
DAGHER IBRAHIM B.OfficerSaleJul 18, 2024190,000
HARTOUNIAN HARTOUNChief Operating OfficerStock Award(Grant)Jun 23, 202430,000
LEBOVITS CHAIMChief Executive OfficerPurchaseMay 27, 20243,165,710
LINDBORG STACY R. PH.D.Chief Executive OfficerStock Award(Grant)Mar 10, 2024423,435
NAOR NIRDirectorStock Award(Grant)Jun 18, 202311,999
PATLIS ALLAChief Financial OfficerStock Award(Grant)Mar 10, 202465,246

Institution ownership

BCLI institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC8.06%459,8461.03MSep 29, 2024
Abner Herrman & Brock Llc2.55%145,500324.46KSep 29, 2024
Vanguard Group Inc1.77%100,710224.58KSep 29, 2024
Geode Capital Management, LLC0.80%45,522101.51KSep 29, 2024
Blackrock Inc.0.44%25,17456.14KSep 29, 2024
Liberty Wealth Management LLC0.40%22,67750.57KSep 29, 2024

Fund ownership

BCLI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.24%70,735157.74KSep 29, 2024
Fidelity Extended Market Index Fund0.50%28,43163.40KOct 30, 2024
Vanguard Extended Market Index Fund0.47%26,73459.62KSep 29, 2024
Fidelity Total Market Index Fund0.17%9,56421.33KOct 30, 2024
Fidelity Series Total Market Index Fund0.12%7,07915.79KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.06%3,2487.24KOct 30, 2024